DRUG COMPARISON
Finasteride vs Tadalafil for BPH: Prostate-Directed Treatment vs Urinary + Erectile Priorities
Finasteride and tadalafil treat BPH through different mechanisms. Finasteride is a slow-onset 5-alpha-reductase inhibitor used as a prostate-directed strategy, while tadalafil 5 mg once daily is approved for BPH symptoms and is also used for erectile dysfunction. Tadalafil does not shrink the prostate like a 5-ARI. The comparison becomes especially relevant when urinary symptoms and erectile function are both important treatment goals.
Decision snapshot
| Search intent | finasteride vs tadalafil for BPH |
|---|---|
| Main concern | Comparing a 5-ARI with tadalafil when BPH and sexual priorities may overlap |
| What this page can do | Explain evidence, mechanism, trade-offs and questions to discuss with a clinician. |
| What this page cannot do | Diagnose the cause, choose a prescription, or tell you to start, stop or switch treatment. |
Two different reasons a clinician might choose them
Finasteride is usually considered when prostate enlargement and long-term progression risk matter. Tadalafil can improve BPH symptom scores without using a prostate-shrinking mechanism and has the additional ED indication. This means the patient profile that makes each medicine attractive can be different even when both appear in the same BPH treatment menu.
Sexual function changes the decision
Finasteride can cause sexual adverse effects in some men. Tadalafil is used to treat erectile dysfunction, but that does not make it automatically preferable: tadalafil has cardiovascular interaction issues and must not be used with nitrates. The correct comparison is not “which one is better for sex?” but whether the person has ED, what medicines he takes, cardiovascular safety, prostate size and the urinary treatment goal.
They can also be used together for a limited role
The tadalafil prescribing information includes a BPH treatment context in which tadalafil is used with finasteride to initiate therapy for up to 26 weeks. That is a clinician-directed strategy, not a general invitation to combine medicines. It illustrates that the drugs can complement rather than merely compete with each other.
Direct comparison
| Factor | Finasteride | Tadalafil |
|---|---|---|
| Class | 5-alpha-reductase inhibitor | PDE5 inhibitor |
| Main BPH role | Prostate-directed, gradual | Improves BPH symptoms without prostate shrinkage |
| ED indication | No | Yes |
| Prostate shrinkage | Yes, in appropriate patients | No |
| Important trade-off | Sexual adverse effects can occur | Nitrate contraindication; headache and other PDE5 effects |
| Onset frame | Months | Symptoms can improve sooner than 5-ARI prostate effects |
This table is an educational summary. Individual suitability depends on diagnosis, prostate findings, blood pressure, cardiovascular history, other medicines, treatment goals and side-effect tolerance.
How to use this page as a decision tool
This page is designed for someone who is already close to a treatment decision. Instead of giving a generic overview of enlarged prostate, it focuses on the exact trade-off behind the search: comparing a 5-ari with tadalafil when bph and sexual priorities may overlap. Write down the symptom that is driving the search, what changed after treatment, and what outcome matters most over the next three to six months. A weak stream, frequent urgency, repeated nighttime trips and sexual side effects are not interchangeable problems, even when they appear under the same BPH diagnosis.
What should be measured before a switch or escalation?
A useful follow-up compares the same outcomes before and after treatment. Track stream strength, hesitation before urine starts, straining, stop-start flow, the sense of incomplete emptying, daytime frequency, urgency and nighttime bathroom trips. If sexual function is part of the decision, track desire, erection quality and ejaculation separately. If dizziness or blood-pressure symptoms are involved, record when they happen and whether they are linked to standing up, exercise, alcohol or other medicines.
Objective evaluation can be just as important as the symptom diary. Depending on the situation, a clinician may use urinalysis, PSA-related testing, post-void residual, uroflowmetry, imaging, cystoscopy or urodynamic testing. The point is not to order every test. It is to avoid repeatedly changing medication when the underlying problem has not been defined well enough.
Red flags that should override the comparison
Search intent stops mattering when urgent symptoms appear. Inability to urinate, blood in the urine, urinary symptoms with fever or chills, or severe lower-abdominal or urinary-tract pain require prompt medical assessment. Recurrent urinary infections, worsening kidney function, repeated retention episodes or a persistently large post-void residual may also change the treatment conversation from “which pill?” to whether further testing or a procedure is appropriate.
For non-urgent problems, the goal is shared decision-making rather than internet prescribing. A well-structured comparison can help you understand mechanisms, timelines and trade-offs. It cannot determine whether the prostate is actually the cause of the symptoms, whether a drug is safe with your other medicines, or whether the benefits outweigh the risks in your specific medical history.
Questions worth taking to a clinician
- Is BPH definitely the main cause of my symptoms, or should another urinary problem be ruled out?
- Is my prostate size or progression risk important to this treatment choice?
- What benefit should I reasonably expect, and over what timeline?
- Which side effects are most relevant to my priorities?
- Could any prescription, over-the-counter medicine or supplement be contributing to the problem?
- If this treatment is not enough, what is the next logical mechanism to consider?
- At what point would testing or a procedure be more useful than another medication change?
Related high-intent guides
Match the information to your symptom pattern
The assessment route is designed to organize the concern behind this search. It is educational, not a diagnosis, and it should not replace medical evaluation.
Urinary & Vitality AssessmentFrequently asked questions
Can tadalafil replace finasteride for BPH?
It can be a different BPH treatment path, but it does not replicate finasteride’s prostate-shrinking mechanism.
Which is better if I also have ED?
Tadalafil may be especially relevant because it is approved for ED and BPH, but cardiovascular safety, nitrates, prostate findings and other factors still determine suitability.
Can finasteride and tadalafil be taken together?
The CIALIS label includes use with finasteride to initiate BPH treatment for up to 26 weeks. Combination therapy should be prescribed and monitored by a clinician.
Does tadalafil shrink the prostate?
No. Its BPH benefit comes through a different mechanism.
Does finasteride help erections?
Finasteride is not an ED treatment and can cause sexual adverse effects in some men.
Does a weak stream always mean BPH?
No. BPH is common, but similar urinary symptoms can come from bladder problems, infection, prostatitis, urethral narrowing, neurologic disease, medicines and other causes. Persistent or worsening symptoms deserve clinical evaluation.
When is urinary trouble urgent?
Seek prompt medical care if you cannot urinate at all, have blood in the urine, have urinary symptoms with fever or chills, or have severe lower-abdominal or urinary-tract pain.
Can I change a prescription based on an online article?
No. Do not start, stop, restart, double, split or switch a prescription based only on online information. Use the article to prepare questions for the prescriber who knows your diagnosis, other medicines and risk factors.
Can supplements replace prescription BPH treatment?
Do not assume equivalence. Evidence varies by supplement, and supplement quality can vary. A supplement should not be treated as a prescription substitute without discussing the reason for treatment and the evidence with a clinician.
Can BPH treatment affect sexual function?
Yes. Depending on the medicine, changes can involve libido, erections, ejaculation or semen volume. The pattern differs by drug class and person, so sexual priorities belong in shared decision-making.
Does prostate size always match symptom severity?
No. A larger prostate can cause modest symptoms while a smaller enlargement can interfere substantially with urination. Symptoms, examination findings and objective testing all help define the problem.
What tests might be used when symptoms persist?
Depending on the situation, evaluation can include history, physical examination, urinalysis, PSA-related testing, post-void residual, uroflowmetry, imaging, cystoscopy or urodynamic testing.
Sources used for this page
- FDA: CIALIS (tadalafil) prescribing information
- NIDDK: Enlarged Prostate (BPH)
- AUA: BPH guideline listing (2026)
Evidence summaries are deliberately conservative. Medical guidance changes, and individual treatment decisions require a qualified clinician.